Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada.
Merck & Co., Inc., Kenilworth, New Jersey.
Proteins. 2019 Mar;87(3):236-244. doi: 10.1002/prot.25644. Epub 2019 Jan 4.
Peptide-based therapeutics are an alternative to small molecule drugs as they offer superior specificity, lower toxicity, and easy synthesis. Here we present an approach that leverages the dramatic performance increase afforded by the recent arrival of GPU accelerated thermodynamic integration (TI). GPU TI facilitates very fast, highly accurate binding affinity optimization of peptides against therapeutic targets. We benchmarked TI predictions using published peptide binding optimization studies. Prediction of mutations involving charged side-chains was found to be less accurate than for non-charged, and use of a more complex 3-step TI protocol was found to boost accuracy in these cases. Using the 3-step protocol for non-charged side-chains either had no effect or was detrimental. We use the benchmarked pipeline to optimize a peptide binding to our recently discovered cancer target: EME1. TI calculations predict beneficial mutations using both canonical and non-canonical amino acids. We validate these predictions using fluorescence polarization and confirm that binding affinity is increased. We further demonstrate that this increase translates to a significant reduction in pancreatic cancer cell viability.
基于肽的疗法是小分子药物的替代品,因为它们具有更高的特异性、更低的毒性和易于合成。在这里,我们提出了一种利用最近出现的 GPU 加速热力学积分 (TI) 带来的显著性能提升的方法。GPU TI 促进了针对治疗靶点的肽的非常快速、高度准确的结合亲和力优化。我们使用已发表的肽结合优化研究来对 TI 预测进行基准测试。发现涉及带电侧链的突变预测不如非带电侧链准确,并且使用更复杂的 3 步 TI 方案在这些情况下可以提高准确性。对于非带电侧链,使用 3 步方案要么没有效果,要么有害。我们使用经过基准测试的管道来优化一种与我们最近发现的癌症靶点 EME1 结合的肽。TI 计算使用经典和非经典氨基酸预测有益的突变。我们使用荧光偏振法验证这些预测,并证实结合亲和力增加。我们进一步证明这种增加转化为胰腺癌细胞活力的显著降低。